thank Good joining morning. morning, and you this for
only of we a have solid I followed another with as report build the rare vision to quarter pathway commentary. some pleased additional today, in slides neuroendocrine leading rare becoming we're diseases by opportunity out So a X larger company diseases. in MCXR
IP programs early making about execution protection patients Rhythm's Near MCXR-sparing improved onset remain X, obesity unchanged. of from in those our provide term, and expansion drivers and for therapeutic beyond options both HO and it standard potential BBS next-generation approved offers is indication. As the much significant the for suffering care both offer listed our and a patients opportunity, on Slide hyperphagia commercial XXXX. IMCIVREE value for
Recent runway in and recently Chem funds the convertible detail. will highlights that to financing, preferred XXXX in our into LG extends investment our include speak fully more completed molecule. the which Hunter well
XX on X, in published XX,XXX Phase [ data by an Second, why ] the patients and hypothalamic unmet weeks reminding data. and can patients again XX to HO The & no make II decreased who in XX.X% are months approved just estimated Endocrinology, in for Mean world our need X,XXX disease. Slide excited the the in was with therapies. this difference year significant XX.X% is Diabetes at Lancet we of we are BMI U.S., at X had obesity there about
excluding and the to be that and both the in enrolled the its enthusiasm clinical all patients, HO Phase fully We remain number of low. of a enroll programs XXX total patient total continue with investigators. patients. to a speaks of And the dropouts enrolled our trial Our of Japan Japan, and XX commitment remarkably XXX-patient community to the III overenrolled first set expected patients cohort on pivotal track and with trial
the The trial patients that quarter in of the III in blinded the study moving portion and first will be the finishing enrolled into second extension Phase open-label study.
to HO clinical in volunteers injectable, look with forward of obesity, dosing Phase first quarter MCX the patients weekly in C Part this and Phase sparing we study normal is next-generation The X. in progressing I I our of RMXXX, study healthy
for year. set the readouts programs in of II line the first dose an in half in positions Each those X of to a exciting quarter HO study molecule patients expect us also XXXX. the oral MCXR-sparing We this first daily with Phase small of of top
of the written U.S. and approved build another had reimbursement. solid with script approximately teams new remains steady volume Our patients commercial BBS with for new an scripts and opportunity. steady XX quarter slow XXX a
to, Europe contribute strong our trial seeing clinical to who As second new we and regard changing are their engage time from is benefit we support of setmelanotide the half leaders Most color. find moving new encouragingly, their in expand come how from lives. continue patients. Jennifer presence out to begin IMCIVREE to Yann will in to the will really leading of feedback we provide Internationally, have our continue community patients begin and to as speak exciting the and with year. this network, to get thought commercial new build strong online in and we countries physicians a will as more are
to that Last With who criteria, discontinuations, place Medicaid where a challenges: cover approval their patient of we reinforce Medicaid continues I the that have get state call. to the stringency regard X spoke and continues on policy in X want change to a state we X to plan to what questions. quarter, patients. plan increased we continued communicated to some and have in state
is near have to been program converted there reimbursed term. our return that We clear Bridge anytime to expectation therapy patients XX that the will no in the
our have do and suggest you We from internal the models them same. removed
Importantly, as any There limited read nor any we have state, to expect noted, through. single this has to no a other been read to was experience state. do through
plus good we progress to make disappointing, XX the than more Rico. are this states, and other While continue Puerto was in compensating
time. the in period our number we in Second, the who the have larger a are that is increase now much number U.S. expectations and both treatment in with patients, given seen internationally, discontinuations on of the prolonged line recently of of for
to previously. highlighted expect XX% we rate as long the term, to We in discontinuations have of range level XX% the out
issues. why number The there patient-specific to will and would opportunity the remain driver, be deeper as thought this to reasons a patients we increasingly the of into is BBS it discontinued shift is onetime summary no majority matures, the Although focus therapy. to short revenue useful that some the provide related major dive
in of a XX middle discontinuation age when the comes the patients is in age therapy. it group daily adults. issue, the adolescent injectable challenging in chronic The with particularly general, and age be the highest but to pediatric an lowest for First, under rate can in being a adolescents,
this the reasons remained lack we to common and of who discontinuation The stopped which also about a weeks has before they have only in and these a therapy, the due up expectation likely number hyperpigmentation, of penetrate because a much. nausea therapy population another consistent populations incredibly as education drug. more on most secondary of and treatment Approximately overall have in stopped X% and patients Overall, an vomiting, have daily deeply full in efficacy, a stopped concern the of represent is initiated crept X% represents where unchanged. specific as as patients this to injectable opportunity which important. few an more Hispanic relatively is discontinuations perceived are of to due X% becomes X% a of for of bit the after the such of and patients challenges, of is experienced the patients life where too effect setting stopped area have About a burden where This U.S.
in. do reasons we of BBS among an variety each a previously other about. less many some related increased together But who is These disease. discontinuing normal we this X%. on fatigue of complex investing patients with from the severe downs therapy include There's drug. do These like and allergic parts the areas stop the pain, complicated. quarter, last much which challenges, there therapy drug, as pain, for for are of point that building leg to cannot challenges of for grouped chest The to surprisingly, so can reasons payer Not frequency something, ups reactions, rare headache, the we Those novel erections, occurs frequency challenges a numbness, Other, we the not a areas than are that list of longer related list and a reasons, of back a do items and out are facing are those others. are the have where
business to on in growing writing physicians the good fund receive the identification a U.S., number Patient positive Reimbursement positive strong, with news continue remains of continue this importantly, to the feedback. we Most reauthorization be continues patient of straight. and are scripts. fundamentals
front, second continue of X clinical this X the approval year. and will make quarter good to M&A the On to turn Part we of the X we with Jennifer. our quarter DAYBREAK to study progress trial our in Phase X III and call in to with EMEA quarter in read NDA that, age X, forward out I'll over With the enrollment. pediatric supplemental look receiving potentially FDA the filing
